(Q37097386)

English

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

scientific article published on 11 October 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

based on heuristic

inferred from title

lessons learned

1 reference

based on heuristic

inferred from title

author name string

Suhrad G Banugaria

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sean N Prater

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Judeth K McGann

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jonathan D Feldman

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jesse A Tannenbaum

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Carrie Bailey

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Renuka Gera

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Robert L Conway

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

David Viskochil

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Joyce A Kobori

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Amy S Rosenberg

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Priya S Kishnani

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

11 October 2012

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Genetics in Medicine

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

123-131

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

The impact of antibodies in late-onset Pompe disease: a case series and literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

The emerging phenotype of long-term survivors with infantile Pompe disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Risk factors for inhibitor formation in haemophilia: a prevalent case-control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Is there a common mechanism linking muscle wasting in various disease types?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Pompe disease diagnosis and management guideline.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Factors influencing the immunogenicity of therapeutic proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Human immune response to recombinant human proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Immunomodulation with intravenous immunoglobulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

29 September 2017

Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

27 June 2018

Bortezomib: a new player in pre- and post-transplant desensitization?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

Elimination of antibodies to recombinant enzyme in Pompe's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744338

3 September 2018

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23060045

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23060045

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/23060045

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23060045

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/GIM.2012.110

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37097386&oldid=2199863986"